Elviira Seppet

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Characterization of Hemorrhagic Fever with Renal Syndrome Caused by Hantaviruses, Estonia

A. Plyusnin, Å. Lundkvist, V. Vasilenko, 2007, Emerging infectious diseases.

Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection

M. Ots-Rosenberg, Ž. Riispere, E. Seppet, 2017, BMC Nephrology.

IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences.

M. Ots-Rosenberg, A. Laurinavičius, Ž. Riispere, 2016, Medicina.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.